Citations

Clear

382 citation(s) found for "Shapiro, CL".

p21 produces a bioactive secretome that places stressed cells under immunosurveillance
Sturmlechner, Ines , Sine, Chance , Deursen, Erik-Jan van, Jeganathan, Karthik B. , Hamada, Naomi, Grašič, Jan , Friedman, David J. , Stutchman, Jeremy, Can, İsmail , Hamada, Masakazu , Lim, Do Young , Lee, Jeong‐Heon , Ördög, Tamás , Laberge, Rémi-Martin , Baker, Darren J. , Deursen, Jan M. van , Sine, Chance C, van Deursen, Erik-Jan, Jeganathan, Karthik B , Friedman, David , Stutchman, Jeremy T, Can, Ismail , Lim, Do Young , Lee, Jeong-Heon , Ordog, Tamas , Shapiro, Virginia S , Baker, Darren J , Li, Hu , van Deursen, Jan M , Sturmlechner, Ines , Zhang, Cheng , Hamada, Masakazu, Shapiro, Virginia Smith

Mayo Clinic

Science | October 28, 2021 | Volume: 374 | Issue: 6567 | Pages: No page available

10.1126/science.abb3420 | PMID 34709885 Get It

The clock is ticking for senescent cells Senescent cells promote their own recognition and removal through the immune system by generating a bioactive secretome called the senescence-associated secretory phenotype (SASP). Sturmlechner et al . report that the cell cycle regulator p21 directs an early form of the SASP, which they call the p21-activated secretory phenotype (PASP) (see the Perspective by Reen and Gil). As part of the PASP, the chemokine CXCL14 attracts macrophages, which monitor stressed cells expressing elevated p21. If stressed cells recuperate and p21 levels return to normal within 4 days, then macrophages disengage from their targets. Otherwise, macrophages recruit cytotoxic T cells that facilitate target cell removal. Other cell cycle regulators such as p16 can induce many factors overlapping with the PASP, but p21 uniquely drives this CXCL14-mediated “timer” mechanism of senescent cell immunosurveillance. —STS
American Medical Society for Sports Medicine Position Statement: Principles for the Responsible Use of Regenerative Medicine in Sports Medicine
Finnoff, Jonathan T. , Awan, Tariq M. , Borg‐Stein, Joanne , Harmon, Kimberly G. , Herman, Daniel C. , Malanga, Gerard A. , Master, Zubin , Mautner, Kenneth , Shapiro, Shane A. , Mautner, Kenneth R , Shapiro, Shane , Finnoff, Jonathan T , Master, Zubin , Harmon, Kimberly G

Mayo Clinic

Clinical Journal of Sport Medicine | October 26, 2021 | Volume: 31 | Issue: 6 | Pages: 530-541

10.1097/jsm.0000000000000973 | PMID 34704973 Get It

Abstract: Many sports medicine physicians are currently considering introducing regenerative medicine into their practice. Regenerative medicine and the subclassification of orthobiologics are a complicated topic and have produced widely varying opinions. Although there is concern by government regulators, clinicians, scientists, patient advocacy organizations, and the media regarding the use of regenerative medicine products, there is also excitement about the potential benefits with growing evidence that certain regenerative medicine products are safe and potentially efficacious in treating musculoskeletal conditions. Sports medicine physicians would benefit from decision-making guidance about whether to introduce orthobiologics into their practice and how to do it responsibly. The purpose of this position statement is to provide sports medicine physicians with information regarding regenerative medicine terminology, a brief review of basic science and clinical studies within the subclassification of orthobiologics, regulatory considerations, and best practices for introducing regenerative medicine into clinical practice. This information will help sports medicine physicians make informed and responsible decisions about the role of regenerative medicine and orthobiologics in their practice.
Response to Rucaparib in BRCA-Mutant Metastatic Castration-Resistant Prostate Cancer Identified by Genomic Testing in the TRITON2 Study
Loehr, Andrea , Patnaik, Akash , Campbell, David , Shapiro, Jeremy , Bryce, Alan H. , McDermott, Ray , Sautois, Brieuc , Vogelzang, Nicholas J. , Bambury, Richard , Voog, Éric , Zhang, Jingsong , Hussain, Arif , Ryan, Charles J. , Merseburger, Axel S. , Daugaard, Gedske , Heidenreich, Axel , Fizazi, Karim , Higano, Celestia S. , Krieger, Laurence E. , Watkins, Simon P. , Despain, Darrin , Simmons, Andrew D. , Dowson, Melanie, Golsorkhi, Tony, Chowdhury, Simon, Abida, Wassim , Ryan, Charles J , Daugaard, Gedske , Heidenreich, Axel , Sternberg, Cora N , Watkins, Simon P , Simmons, Andrew D , Golsorkhi, Tony , Bryce, Alan H , Vogelzang, Nicholas J , McDermott, Ray , Patnaik, Akash , Piulats, Josep M.

Mayo Clinic

Clinical Cancer Research | October 1, 2021 | Volume: 27 | Issue: 24 | Pages: 6677-6686

10.1158/1078-0432.ccr-21-2199 | PMID 34598946 Get It

Abstract Purpose: The PARP inhibitor rucaparib is approved in the United States for patients with metastatic castration-resistant prostate cancer (mCRPC) and a deleterious germline and/or somatic BRCA1 or BRCA2 (BRCA) alteration. While sequencing of tumor tissue is considered the standard for identifying patients with BRCA alterations (BRCA+), plasma profiling may provide a minimally invasive option to select patients for rucaparib treatment. Here, we report clinical efficacy in patients with BRCA+ mCRPC identified through central plasma, central tissue, or local genomic testing and enrolled in TRITON2. Patients and Methods: Patients had progressed after next-generation androgen receptor–directed and taxane-based therapies for mCRPC and had BRCA alterations identified by central sequencing of plasma and/or tissue samples or local genomic testing. Concordance of plasma/tissue BRCA status and objective response rate and prostate-specific antigen (PSA) response rates were summarized. Results: TRITON2 enrolled 115 patients with BRCA+ identified by central plasma (n = 34), central tissue (n = 37), or local (n = 44) testing. Plasma/tissue concordance was determined in 38 patients with paired samples and was 47% in 19 patients with a somatic BRCA alteration. No statistically significant differences were observed between objective and PSA response rates to rucaparib across the 3 assay groups. Patients unable to provide tissue samples and tested solely by plasma assay responded at rates no different from patients identified as BRCA+ by tissue testing. Conclusions: Plasma, tissue, and local testing of mCRPC patients can be used to identify men with BRCA+ mCRPC who can benefit from treatment with the PARP inhibitor rucaparib.
Endoscopic Browlift in Patients With Receding Hairlines
Boonipat, Thanapoom , Hebel, Nathan , Lin, J, Frank, Konstantin , Möllhoff, Nicholas, Cotofana, Sebastian, Cotofana, Sebastian , Bradley, Elizabeth A. , Shapiro, Daniel, Mardini, Samir

Mayo Clinic

Journal of Craniofacial Surgery | October 1, 2021 | Volume: 33 | Issue: 2 | Pages: 615-619

10.1097/scs.0000000000008156 | PMID 34593745 Get It

Abstract Patients with receding or high hairlines have traditionally been considered unfavorable candidates for endoscopic brow lift as this can further lengthen the hairline. We analyzed outcomes in patients that underwent a novel endoscopic brow lift technique with placement of incisions and anchoring Endotine Forehead Devices (CoApt Systems Inc, Palo Alto, CA, USA) directly at the natural forehead crease lines, in an effort to minimize elevation of the hairline, whereas providing well-hidden scars. We retrospectively reviewed all patients who underwent this new Endotine and incision placement between 2016 and 2020. Preoperative and postoperative photographs of all patients were analyzed to determine the postoperative changes in brow elevation and forehead length proportion (defined as length from cranium to chin). The forehead length proportion was unchanged pre- and post-operatively, with no statistically significant differences noted (P = 0.48). The average brow position elevation ranged from 2.78 mm in the medial location to 5.05 mm in the lateral location. All patients were happy with their appearance and had improved visual fields postoperatively. The forehead scars healed well and were well hidden in forehead rhytids at long term follow-up. This novel endoscopic brow lift technique provides an option to utilize a minimally invasive approach in patients with receding hairline. With this technique, visible scars were minimized, whereas still being able to achieve reasonable brow elevation. Thus, our approach enables long term maintenance of brow elevation with inconspicuous scars in the forehead.
Flow Diversion for Middle Cerebral Artery Aneurysms: An International Cohort Study
Diestro, Jose Danilo Bengzon , Adeeb, Nimer , Dibas, Mahmoud , Boisseau, William , Harker, Pablo , Brinjikji, Waleed , Xiang, Sishi, Joyce, Evan, Shapiro, Maksim , Raz, Eytan , Pickett, Gwynedd E. , Alotaibi, Naif M. , Regenhardt, Robert W. , Spears, Julian , Burkhardt, Jan‐Karl , Hafeez, Muhammad Ubaid , Kan, Peter , Nossek, Erez , Zhang, Hongqi , Rinaldo, Lorenzo , Stapleton, Christopher J. , Rabinov, James D. , Patel, Aman B. , Marotta, Thomas R. , Dmytriw, Adam A. , Burkhardt, Jan-Karl , Kan, Peter , Rinaldo, Lorenzo , Lanzino, Giuseppe , Dmytriw, Adam A , Dibas, Mahmoud , Diestro, Jose Danilo B , Harker, Pablo , Regenhardt, Robert W , Hafeez, Muhammad U , Burkhardt, Jan‐Karl , Parra-Fariñas, Carmen , Bernstock, Joshua D. , Griessenauer, Christoph J. , Grandhi, Ramesh , Taussky, Philipp , Hong, Tao , Lanzino, Giuseppe , Roy, Daniel C.

Mayo Clinic

Neurosurgery | September 8, 2021 | Volume: 89 | Issue: 6 | Pages: 1112-1121

10.1093/neuros/nyab365 | PMID 34624100 Get It

Abstract BACKGROUND Open surgery has traditionally been preferred for the management of bifurcation middle cerebral artery (MCA) aneurysms. Flow diverting stents present a novel endovascular strategy for aneurysm treatment. OBJECTIVE To add to the limited literature describing the outcomes and complications in the use of flow diverters for the treatment of these complex aneurysms. METHODS This is a multicenter retrospective review of MCA bifurcation aneurysms undergoing flow diversion. We assessed post-treatment radiological outcomes and both thromboembolic and hemorrhagic complications. RESULTS We reviewed the outcomes of 54 aneurysms treated with flow diversion. Four (7.4%) of the aneurysms had a history of rupture (3 remote and 1 acute). Fourteen (25.9%) of the aneurysms already underwent either open surgery or coiling prior to flow diversion. A total of 36 out of the 45 aneurysms (80%) with available follow-up data had adequate aneurysm occlusion with a median follow-up time of 12 mo. There were no hemorrhagic complications but 16.7% (9/54) had thromboembolic complications. CONCLUSION Flow diverting stents may be a viable option for the endovascular treatment of complex bifurcation MCA aneurysms. However, compared to published series on the open surgical treatment of this subset of aneurysms, flow diversion has inferior outcomes and are associated with a higher rate of complications.
Stroke‐Related Mortality in the United States–Mexico Border Area of the United States, 1999 to 2018
Khan, Safi U. , Kalra, Ankur , Yedlapati, Siva H. , Dani, Sourbha S. , Shapiro, Michael D. , Nasir, Khurram , Virani, Salim S. , Michos, Erin D. , Alkhouli, Mohamad , Alkhouli, Mohamad , Khan, Safi , Kalra, Ankur , Michos, Erin D , Shapiro, Michael D , Dani, Sourbha S

Mayo Clinic

Journal of the American Heart Association | July 3, 2021 | Volume: 10 | Issue: 13 | Pages: No page available

10.1161/jaha.120.019993 | PMID 34212760 Get It

BACKGROUND The United States (US)‐Mexico border is a socioeconomically underserved area. We sought to investigate whether stroke‐related mortality varies between the US border and nonborder counties. METHODS AND RESULTS We used death certificates from the Centers for Disease Control and Prevention Wide‐Ranging Online Data for Epidemiologic Research database to examine stroke‐related mortality in border versus nonborder counties in California, Texas, New Mexico, and Arizona. We measured average annual percent changes (AAPCs) in age‐adjusted mortality rates (AAMRs) per 100 000 between 1999 and 2018. Overall, AAMRs were higher for nonborder counties, older adults, men, and non‐Hispanic Black adults than their counterparts. Between 1999 and 2018, AAMRs reduced from 55.8 per 100 000 to 34.4 per 100 000 in the border counties (AAPC, −2.70) and 64.5 per 100 000 to 37.6 per 100 000 in nonborder counties (AAPC, −2.92). The annual percent change in AAMR initially decreased, followed by stagnation in both border and nonborder counties since 2012. The AAPC in AAMR decreased in all 4 states; however, AAMR increased in California’s border counties since 2012 (annual percent change, 3.9). The annual percent change in AAMR decreased for older adults between 1999 and 2012 for the border (−5.10) and nonborder counties (−5.01), followed by a rise in border counties and stalling in nonborder counties. Although the AAPC in AAMR decreased for both sexes, the AAPC in AAMR differed significantly for non‐Hispanic White adults in border (−2.69) and nonborder counties (−2.86). The mortality decreased consistently for all other ethnicities/races in both border and nonborder counties. CONCLUSIONS Stroke‐related mortality varied between the border and nonborder counties. Given the substantial public health implications, targeted interventions aimed at vulnerable populations are required to improve stroke‐related outcomes in the US‐Mexico border area.
Abstract 1874: Circumferential and Radial Left Ventricular Mechanics in Elderly Canines with Hypertensive Heart Disease
Shapiro, Brian P. , Meyer, Donna , Redfield, Margaret M. , Kořínek, Josef , Lam, Carolyn S.P.

Mayo Clinic

Circulation | July 3, 2021 | Volume: 116 | Issue: suppl_16 | Pages: No page available

10.1161/circ.116.suppl_16.ii_401-b Get It

Introduction: Cross-sectional studies in patient with hypertensive heart disease (HHD) and heart failure with normal ejection fraction (HFnlEF) suggested impairment of longitudinal myocardial mechanics as assessed by tissue Doppler imaging. It has been suggested that enhanced circumferential, and/or radial LV mechanics or LV remodeling compensates for depression in longitudinal function and thus, preserves EF in HHD or HFnlEF. Hypothesis : We hypothesized that if longitudinal performance is depressed, whether due to increased afterload or to intrinsic myocardial dysfunction, circumferential and radial LV mechanics would also be effected. To test this hypothesis, we used an aged canine model of hypertension. Methods: Elderly dogs (n=22) underwent bilateral renal wrapping to induce hypertension. 2D echocardiography (mid-short axis views) was performed before and 8 weeks after renal wrapping; peak radial (PR) and peak circumferential (PC) regional strains were measured by speckle tracking averaging data from 6 segments. Ejection fraction (EF), LV mass index (LVMI), systolic blood pressure (SBP), and circumferential wall stress (CWS) were assessed as well. Results : See table . PR correlated with PC (r=0.65), EF (r=0.67), LWMI (r=0.71) and CWS (r=0.58) (p<0.005 for all). PC correlated also with EF (r=0.60), LWMI (r=0.49) and CWS (r=0.48) (p<0.01 for all). The relationship between EF and CWS (r 2 =0.64, p<0.001) was modified by the addition of either PC (r 2 =0.74, p for PC =0.005) or PR strain(r 2 =0.69, p for PR =0.04). Conclusions : These data show that development of hypertension with LV hypertrophy does not enhance but impairs circumferential and radial LV mechanics as assessed with strain imaging, and that like EF, circumferential and radial strain are related to afterload (wall stress). However, both confer additional information regarding contractility. Conclusions regarding myocardial function based on strain imaging must account for its load dependence.
Tonic Inhibition of Sodium Reabsorption by Na + /K + ‐ATPase in the Renal Proximal Tubule
Mukherji, Shreya T. , Brambilla, Luca , Mayes, Isabella, Kutz, Laura C. , Romero, Michael L, Shapiro, Joseph, Blanco, Gustavo , Xie, Zijian , Pierre, Sandrine V. , McDermott, Jeff S. , Haller, Steven T. , Liu, Jiang , Shapiro, Joseph, McDermott, Jeffrey P.

Mayo Clinic

The FASEB Journal | June 10, 2021 | Volume: 35 | Issue: S1 | Pages: No page available

10.1096/fasebj.2021.35.s1.02937 Get It

In the renal proximal tubule (PT), Na + /K + ‐ATPase (NKA) is exclusively located in the basolateral domain. Through its classic ATP‐dependent ion‐pumping function, NKA generates the Na + gradient that drives apical Na + reabsorption, mostly through Na + /H + exchanger (NHE3). Accordingly, activation of NKA‐mediated ion transport decreases natriuresis through activation of basolateral (NKA) and apical Na + reabsorption (NHE3). In contrast, pharmacological evidence suggests that activation of the more recently discovered NKA signaling function triggers a cellular redistribution of NKA and NHE3 that decreases transcellular Na + flux in cultured PT cells. To obtain genetic evidence of this NKA/Src mechanism in the PT and asses its physiological importance, we used a knockdown and rescue approach in pig renal epithelial cells (LLC‐PK1). Additionally, we genetically targeted NKA α1 in the mouse PT by crossing mice expressing a sodium glucose co‐transporter 2 promoter driven Cre transgene with Floxed NKA α1 mice (PTα1 ‐/‐ ). Knockdown of 90% of NKA α1 in PT LLC‐PK1 cells increased transepithelial 22 Na flux by 2‐fold, activated NHE3 (50% decrease in inhibitory phosphorylation), and increased basolateral Na + /HCO 3 ‐ cotransporter (NBCe1A) protein content. In the PTα1 ‐/‐ mouse (4‐month males and females in a 1:1 ratio), 70% decrease in PT NKA α1 expression decreased urine output (0.51±0.14 vs 1.57±0.21 mL/24h in PTα1 +/+ , p<0.001, n=16) and absolute Na + excretion (0.14±0.05 vs 0.36±0.05 mmol/24h in PTα1 +/+ , p<0.05, n=8) by 65%, without histological or functional evidence of renal injury. Those changes were driven by increased PT Na + reabsorption, as indicated by a 65% decrease in lithium clearance (4‐month males, 1344±220 vs 3932±697 mL/24h in PTα1 +/+ , p<0.001, n=12) with unchanged GFR. This hyper‐reabsorptive phenotype of PTα1 ‐/‐ mice was coupled to increased membrane abundance of NHE3 and NBCe1A, and rescued upon crossing with floxed NHE3 mice, consistent a NKA/NHE3‐dependent mechanism. A dismantlement of caveolar NKA/Src receptor complex and intracellular redistribution of pY418Src occurred in knockdown NKA α1 PT cells, and was also observed in the PTα1 ‐/‐ hypomorphic mouse. Rescue of PT cells with wild‐type but not Src signaling‐null NKA α1 restored NHE3 and NBCe1A to basal levels, indicative of a role for NKA/Src receptor function in the tonic inhibition of Na + transporters in the PT. Hence, NKA signaling exerts a tonic inhibition on Na + reabsorption by regulating key apical and basolateral Na + transporters. This action, which is lifted upon NKA genetic suppression in cells and in vivo , tonically counteracts NKA's ATP‐driven function of basolateral Na + reabsorption. Strikingly, NKA/Src signaling is not only physiologically relevant, it is functionally dominant over NKA ion‐pumping in the control of PT reabsorption. NKA signaling therefore provides a long sought‐after mechanism for the natriuretic action of endogenous NKA ligands such as cardiotonic steroids.
Heterogeneity of meningeal B cells reveals a lymphopoietic niche at the CNS borders
Brioschi, Simone , Wang, Wei-Le , Peng, Vincent , Wang, Meng , Shchukina, Irina, Greenberg, Zev J. , Bando, Jennifer K. , Jaeger, Natália , Czepielewski, Rafael S. , Swain, Amanda , Mogilenko, Denis A. , Beatty, Wandy L. , Fitzpatrick, James A. J. , Schuettpelz, Laura G. , Fronick, Catrina C. , Smirnov, Igor , Kipnis, Jonathan , Wu, Gregory F. , Gilfillan, Susan , Artyomov, Maxim N. , Fitzpatrick, James A J , Fronick, Catrina C , Kipnis, Jonathan , Shapiro, Virginia S , Wu, Gregory F , Gilfillan, Susan , Cella, Marina , Artyomov, Maxim N , Kleinstein, Steven H , Colonna, Marco , Bando, Jennifer K , Brioschi, Simone , Bayguinov, Peter O. , Shapiro, Virginia Smith , Colonna, Marco

Mayo Clinic

Science | June 3, 2021 | Volume: 373 | Issue: 6553 | Pages: No page available

10.1126/science.abf9277 | PMID 34083450 Get It

Getting around the blood–brain barrier The meninges comprise three membranes that surround and protect the central nervous system (CNS). Recent studies have noted the existence of myeloid cells resident there, but little is known about their ontogeny and function, and whether other meningeal immune cell populations have important roles remains unclear (see the Perspective by Nguyen and Kubes). Cugurra et al. found in mice that a large proportion of continuously replenished myeloid cells in the dura mater are not blood derived, but rather transit from cranial bone marrow through specialized channels. In models of CNS injury and neuroinflammation, the authors demonstrated that these myeloid cells have an immunoregulatory phenotype compared with their more inflammatory blood-derived counterparts. Similarly, Brioschi et al. show that the meninges host B cells that are also derived from skull bone marrow, mature locally, and likely acquire a tolerogenic phenotype. They further found that the brains of aging mice are infiltrated by a second population of age-associated B cells, which come from the periphery and may differentiate into autoantibody-secreting plasma cells after encountering CNS antigens. Together, these two studies may inform future treatment of neurological diseases. Science , abf7844, abf9277, this issue p. eabf7844 , p. eabf9277 ; see also abj8183, p. 396
NCI protocol 10250: A phase II study of temozolomide and olaparib for the treatment of advanced uterine leiomyosarcoma.
Allred, Jacob B., Gano, Katherine, Attia, Steven , Seetharam, ­Mahesh , Boikos, Sosipatros A. , Bui, Nam Q. , Chen, James Lin, Close, Julia , Das, Biswajit , Kochupurakkal, Bose , Trepel, Jane B. , Bui, Nam , Ingham, Matthew , George, Suzanne , Burgess, Melissa , Coté, Gregory M. , Thaker, Premal H. , Ivy, S. Percy , Shapiro, Geoffrey I. , Pommier, Yves G. , Schwartz, Gary K.

Mayo Clinic

Journal of Clinical Oncology | June 2, 2021 | Volume: 39 | Issue: 15_suppl | Pages: 11506-11506

10.1200/jco.2021.39.15_suppl.11506 Get It

11506 Background: Uterine leiomyosarcoma (uLMS) is an aggressive sarcoma subtype with frequent metastatic relapse. After failure of front-line chemotherapy, remaining options provide limited benefit (trabectedin: ORR 11%, mPFS 4.0 mos; pazopanib: ORR 11%, median PFS 2.9 mos; dacarbazine: ORR 9%, mPFS 1.5 mos). Recent molecular studies suggest uLMS harbors characteristic defects in the homologous recombination (HR) DNA repair pathway, including somatic biallelic BRCA2 deletion in 10%, implicating potential sensitivity to PARP-inhibitor based treatment approaches. In preclinical uLMS models in which temozolomide (T, an oral equivalent to dacarbazine) or the PARP inhibitor olaparib (O) showed limited single agent activity, the combination of T + O was highly effective in inhibiting uLMS tumor growth and promoting apoptosis. Methods: NCI protocol #10250 is a single-arm, open-label, multi-center phase II study evaluating T + O in advanced uLMS. Pts had progression on ≥ 1 prior line and ECOG PS ≤ 2. Pts received T 75 mg/m2 PO daily + O 200 mg PO BID days 1-7 in 21-day cycles. Primary endpoint was ORR. A one-stage binomial design was used. If ≥ 5/22 responded, the treatment was considered promising (95% power; α = 0.06). All pts underwent paired tumor biopsies. Correlative assays to evaluate for HR deficiency (whole exome sequencing/RNAseq, RAD51 foci formation) and for intrinsic PARP inhibitor resistance (SLFN11 expression) will be correlated with response. Results: 22 patients were evaluable (median age 55, median prior treatment lines 3). Median follow-up was 10.8 mos. Primary endpoint, ORR within 6 mos of initiating treatment, was 23% (5/22). Overall ORR was 27% (6/22). Median PFS was 6.9 mos (95% CI: 5.4 mos – not estimable (NE)). Median duration of response (DOR) was 12.0 mos (95% CI: 9.5 mos – NE). Hematologic toxicity was common (grade 3/4 neutropenia, 77%; thrombocytopenia 32%) but manageable with dose modification. Correlative assays are ongoing with plans to present at the meeting. An immunohistochemical assay for RAD51 foci has been adapted for uLMS samples and clearly distinguishes BRCA2- deleted and wild-type tumors. Conclusions: NCI 10250 met the prespecified primary efficacy endpoint of ORR in a population of patients with heavily pre-treated uLMS. Responses are durable (median DOR 12 mos). Correlative assays are being completed to evaluate whether uLMS tumors with HR deficiency or with preserved SLFN11 expression are most sensitive to T + O and may underlie durable responses. A randomized study of the combination is planned. Clinical trial information: NCT03880019.